EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Unicycive Therapeutics's enterprise value is $33.54 Mil.
Unicycive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Unicycive Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Unicycive Therapeutics's EV-to-Revenue or its related term are showing as below:
UNCY'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.39 Med: 14.32 Max: 79.27
Current: 49.69
During the past 5 years, the highest EV-to-Revenue of Unicycive Therapeutics was 79.27. The lowest was 1.39. And the median was 14.32.
UNCY's EV-to-Revenue is ranked worse than 77.67% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs UNCY: 49.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Unicycive Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Unicycive Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unicycive Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Unicycive Therapeutics's EV-to-Revenue falls into.
Unicycive Therapeutics's current Enterprise Value is $33.54 Mil.
Unicycive Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unicycive Therapeutics's share price for today is $0.9459.
Unicycive Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unicycive Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Unicycive Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Unicycive Therapeutics (Unicycive Therapeutics) Business Description
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UNCY has been successfully added to your 